vorapaxar

Ligand id: 4047

Name: vorapaxar

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: vorapaxar

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 77.52
Molecular weight 492.24
XLogP 6.44
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Approved to reduce the risk of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).
Mechanism Of Action and Pharmacodynamic Effects
Vorapaxar is an antagonist of the protease-activated receptor-1 (PAR1) expressed on platelets. The effect is to inhibit thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. Drug action reduces the formation of blood clots and reduces the risk of cardiovascular events and stroke. Due to its long receptor dissociation half-life of (~20 hours) it acts effectively in an irreversible fashion. Its very long elimination half-life, means it is long-acting, displaying significant inhibition of platelet aggregation for up to 4 weeks after discontinuation [2].
External links